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Objective: The objective of this study was to evaluate the clinical aspects of the levonorgestrel-releasing
intrauterine system (LNG-IUS) in patients with large adenomyosis associated with dysmenorrhea and/or
heavy menstrual bleeding (HMB).
Materials and methods: Data were collected retrospectively from 48 patients with large adenomyosis
(gestational age  12 weeks during pelvic examination) diagnosed via transvaginal ultrasonography
between January 2008 and December 2009. Clinical outcomes, including symptomatic changes of
dysmenorrhea and HMB, uterine volume change, complications, and the overall success rate were
evaluated in each patient after treatment with the LNG-IUS.
Results: The patients' mean age was 41.7 ± 6.1 years, and the median follow-up duration was 20 months
(range, 3e50 months). Signiﬁcant improvements (p < 0.01) in dysmenorrhea and HMB were observed.
There was no signiﬁcant change in the uterine volume. The most common side effects were prolonged
vaginal spotting (n ¼ 28, 58.3%) and LNG-IUS expulsion (n ¼ 18, 37.5%). Five (10.4%) patients underwent
premature LNG-IUS removal and eight (16.7%) patients underwent hysterectomy. The overall success rate
of the LNG-IUS was 68.8%.
Conclusion: The LNG-IUS is a suitable alternative treatment option for the management of dysmenorrhea
and HMB prior to hysterectomy, for patients with large adenomyosis.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Adenomyosis is a common gynecological disorder characterized
by the presence of endometrial glands and/or stroma in the myo-
metrium [1]. It is an important cause of dysmenorrhea and heavy
menstrual bleeding (HMB), which occur in ~ 65% of women with
adenomyosis and can result in a poor quality of life [2,3]. Tradi-
tionally, the diagnosis of adenomyosis was based on clinical ﬁnd-
ings and pathologic conﬁrmation after hysterectomy. However,
transvaginal ultrasonography (TVS) and magnetic resonance im-
aging have been shown to be accurate, noninvasive methods for
diagnosis [3e6]. The development of such imaging techniques,
signiﬁcantly, offers women the options of medical and/orand Gynecology, CHA Gang-
-ro, Gangnam-gu, Seoul 135-
bstetrics & Gynecology. Publishedminimally invasive surgical treatments. The various medical
treatment modalities for symptomatic adenomyosis include oral
contraceptives, danazol, oral progestins, injectable progestins,
gonadotropin-releasing hormone agonists, and the levonorgestrel-
releasing intrauterine system (LNG-IUS). Minimally invasive sur-
gical methods include uterine artery embolization, endometrial
resection/ablation, and magnetic resonance-guided focused ultra-
sonography [6e10].
The noncontraceptive beneﬁts of the LNG-IUS, particularly the
effects on dysmenorrhea and HMB, have been proven to be effec-
tive against adenomyosis in many clinical trials; a signiﬁcant
decrease in dysmenorrhea and HMB in a majority of women was
observed in ﬁve of these trials [2,3,11e13]. In a randomized com-
parison study, an enhancement in all aspects of the quality of life in
hysterectomy patients was observed with the LNG-IUS during the
1-year follow-up [14]. However, there has been only one case
report about the treatment of large symptomatic adenomyosis with
the LNG-IUS [2]. Therefore, the objective of this study was to spe-
ciﬁcally evaluate the clinical aspects, including symptomaticby Elsevier Taiwan LLC. All rights reserved.
Table 1
Patients' baseline characteristics.
Characteristics Mean ± SD or median
(range), n (%)
Age (y) 41.7 ± 6.1
Gravidity 3 (0e7)
Parity 2 (0e3)
Body weight (kg) 57.8 ± 8.2
Height (cm) 159.6 ± 4.4
BMI (kg/m2) 22.7 ± 3.0
Initial uterine volume (cm3) 253.5 (201e687)
Follow-up duration (mo) 20 (3e50)
Initial symptoms
Heavy menstrual bleeding (HMB), only 10 (20.8)
Dysmenorrhea, only 8 (16.7)
HMB þ dysmenorrhea 30 (62.5)
SD ¼ standard deviation.
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patients with large adenomyosis (gestational age  12 weeks dur-
ing pelvic examination) associated with dysmenorrhea and/or
HMB.
Materials and methods
A total of 48 premenopausal patients (27e53 years) participated
in a retrospective study conducted from January 2008 to December
2009. The patients were diagnosed with adenomyosis using TVS
and had a uterine size  12 gestational weeks during the pelvic
examination along with symptoms of dysmenorrhea and/or HMB.
All patients refused to undergo hysterectomy or use oral contra-
ceptives, and provided informed consent for treatment of symp-
tomatic adenomyosis with the LNG-IUS. This study was approved
by the Institutional Review Board of CHA GangnamMedical Center,
CHA University, Seoul, Korea. The diagnostic criteria for adeno-
myosis with TVS had been reported in previous studies: globular
and/or asymmetric thickening of the uterine wall, myometrial
cysts, distorted and heterogeneous myometrial echotexture, focal
or diffuse heterogeneous myometrial echotexture, a poorly deﬁned
endometrialemyometrial junction, and a poorly deﬁned focus of
abnormal myometrial echotexture [15,16]. The uterine volume was
calculated using the formula for an ellipsoid (volume ¼ 0.52
 length  anteroposterior diameter  transverse diameter).
The LNG-IUS was inserted into the uterine cavity during Days
5e7 of the menstrual cycle of all patients. After insertion of the
LNG-IUS, we recommended follow-up visits every 3e6 months
during the 1st year and every 6e12 months thereafter. Each follow-
up visit typically entailed monitoring symptomatic changes of
dysmenorrhea and/or HMB and TVS examinations to conﬁrm the
uterine volume and location of the LNG-IUS. Symptomatic changes
were evaluated with a visual analog scale (VAS). Preinsertion
symptoms of dysmenorrhea and HMB were assessed using a linear
scale, with the left extreme deﬁned as “no pain or no bleeding”
(0 mm) and the right extreme deﬁned as “worst pain or worst
bleeding I have ever felt” (100 mm). The score itself was deter-
mined by measuring the distance from the left side of the scale to
the point marked by patients as their level of pain and amount of
menstrual blood. Any special events, such as an abrupt onset of
bleeding or spontaneous LNG-IUS expulsion, were recorded as a
complication or side effect. All follow-up data (i.e., symptomatic
changes, side effects, and TVS ﬁndings) were retrospectively
collected and analyzed.
Statistical analyses were performed using SPSS software for
Windows version 20 (SPSS Inc., Chicago, IL, USA). The Shapir-
oeWilk test was used to test the normality of the data. Descriptive
data were expressed as the mean ± standard deviation. Skewed
data were within the median and range. A Wilcoxon signed rank
test was used to compare the subjective changes in symptoms and
the uterine volume prior to and after the LNG-IUS insertion. Sta-
tistical signiﬁcancewas set at p < 0.05. All statistical tests were two-
sided.
Results
During the study period, a total of 176 patients with dysmen-
orrhea and/or HMB were diagnosed with adenomyosis using TVS
and treated with the LNG-IUS. Among these patients, 48 women
showed a uterine volume  12 gestational weeks during the pelvic
examination. The mean age of the 48 enrolled patients was
41.7 ± 6.1 years and the median follow-up duration was 20 months
(3e50 months). The median uterine volume before the LNG-IUS
insertion was 253.5 mL (range, 201e687 mL). The baseline char-
acteristics and initial symptoms of the patients are listed in Table 1.Approximately 60% of the patients had both HMB and dysmenor-
rhea prior to the LNG-IUS insertion.
Themean VAS score for dysmenorrhea and HMB decreased after
the LNG-IUS insertion. The mean symptom score for dysmenorrhea
remarkably decreased from 5.81 ± 2.96 to 2.86 ± 2.8 after 3 months
(p < 0.01); after 36 months, the mean symptom score decreased to
1.4 ± 1.65 (p < 0.01). Themean score for the subjective symptoms of
HMB also decreased continuously similar to dysmenorrhea (from
6.94 ± 2.61 to 3.25 ± 3.02 after 3 months, p < 0.01; and to
0.89 ± 1.27 after 36 months, p < 0.01; Table 2).
The median uterine volume decreased from 253.5 mL to
232.5 mL after 6 months; after 36 months, it had increased to
267mL. Nonetheless, thesewere no signiﬁcant differences between
the initial uterine volume and the volumes at 6 months and 36
months (Figure 1).
The most common side effect was abnormal uterine bleeding.
Twenty-eight patients (58.3%) complained of prolonged vaginal
spotting. Seventeen patients (35.4%) suffered from lower abdom-
inal pain or lower back pain, and 17 patients (35.4%) reported
watery discharge or foul odor from the vagina. However, these side
effects were tolerable in most cases. Only three patients who
complained of prolonged spotting and one patient who complained
of abdominal pain requested the removal of the LNG-IUS.
Eighteen patients (37.5%) reported LNG-IUS expulsion. Most of
the patients (11/18 patients) who experienced LNG-IUS expulsion
wanted to reuse it because they had been satisﬁed with its clinical
effects; however, four of these 11 patients experienced a second
LNG-IUS expulsion. Seven of the 18 patients elected to discontinue
using the LNG-IUS because they wanted to observe their symptoms
without any interventions. Out of the four patients who experi-
enced a second expulsion, one patient had the LNG-IUS reinserted
and after that she did not experience a third expulsion during the
follow-up periods. All expulsions occurred during the ﬁrst 12
months, and most expulsions (n ¼ 15) occurred during the ﬁrst 6
months. There was no signiﬁcant difference in the uterine volume
between the expulsion [266.5 mL (201e687 mL)] and without
expulsion [248.5 mL (201e384 mL)] groups (p ¼ 0.406).
During the follow-up periods, 22 patients (45.8%) continued to
use the LNG-IUS for treating adenomyosis. Five patients (10.4%)
withdrew from treatment with the LNG-IUS owing to complica-
tions. Two patients (4.2%) had the LNG-IUS removed for a preg-
nancy trial, and one patient (2.1%) opted for LNG-IUS removal after
menopause.
A total of eight patients (16.7%) underwent hysterectomy
because of prolonged spotting (n ¼ 3; 6.3%), repeated LNG-IUS
expulsion (n ¼ 3; 6.3%), severe abdominal pain (n ¼ 1; 2.1%), and
a lack of symptomatic improvement in HMB (n ¼ 1; 2.1%).
Table 2
Subjective symptomatic change in dysmenorrhea and HMB before and after LNG-IUS insertion.
Before insertion After insertion
3 mo 6 mo 12 mo 24 mo 36 mo
No. of patients 48 36 17 31 15 9
Dysmenorrhea 58.1 ± 29.6 28.6 ± 28.0* 23.5 ± 20.3* 22.3 ± 25.9* 19.3 ± 19.8* 14.0 ± 16.5*
HMB 69.4 ± 26.1 32.5 ± 30.2* 25.3 ± 17.7* 25.2 ± 26.7* 18.7 ± 16.9* 8.9 ± 12.7*
Data are presented as mean ± SD.
* Signiﬁcant difference relative to the before-insertion variables (Wilcoxon signed rank test; p < 0.01).
HMB ¼ heavy menstrual bleeding; LNG-IUS ¼ levonorgestrel-releasing intrauterine system; SD ¼ standard deviation.
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large symptomatic adenomyosis was 68.8%; this group included
patients who continued to use the LNG-IUS (n ¼ 22), had the LNG-
IUS reinserted after expulsion (n¼ 8), had the LNG-IUS removed for
a pregnancy trial (n ¼ 2), and had chosen to have the LNG-IUS
removed after menopause (n ¼ 1).Discussion
Although the contraindications for intrauterine devices (IUDs;
i.e., LNG-IUS) do not include uterine size, it is recommended that all
IUDs be inserted in uteri at a depth of 6e9 cm [17]. The effective-
ness of the LNG-IUS in patients with large symptomatic adeno-
myosis was established in this study during a median follow-up of
20 months (3e50 months). To the best of our knowledge, this is the
ﬁrst study to evaluate the effectiveness of the LNG-IUS in patients
with large symptomatic adenomyosis, except for one case report
[2]. Despite the large mean uterine volume in this study, we were
able to show a signiﬁcant symptomatic improvement in dysmen-
orrhea and HMB similar to previously reported ﬁndings [3,12,13].
Previously reported uterine volumes ranged from 113mL to 156 mL
[3,12,13], which is relatively small compared to the mean uterine
volume recorded in this study (253.5 mL).
The efﬁcacy of the LNG-IUS for reducing the uterine volume in
cases of adenomyosis is controversial. Signiﬁcant uterine volume
reductions associated with the LNG-IUS were reported by Cho et al
[12] and Sheng et al [13], but not by Bragheto et al [3]. In this study,
there were no signiﬁcant differences in uterine volumes; however,
the volume trend changed from decreasing to increasing at 6Figure 1. Changes in the median uterine volume before and after insertion of the
levonorgestrel-releasing intrauterine system (LNG-IUS). Data were analyzed with the
Wilcoxon signed rank test; no signiﬁcant differences were observed between before
and after LNG-IUS insertion.months after insertion, which is similar to the ﬁndings of Cho et al
[12]. It is difﬁcult to explain the observed changes in the volume
trend. One possibility for this trend is the decline in the levonor-
gestrel concentration in the outer uterus. The local effects of the
LNG-IUS might be sufﬁcient to affect the endometrium, but might
not be strong enough to affect the entire uterus. Bragheto et al [3],
who usedmagnetic resonance imaging tomonitor the effectiveness
of the LNG-IUS for treating patients with adenomyosis, reported a
signiﬁcant reduction in the junctional-zone thickness without any
signiﬁcant reduction in the overall uterine volume. As expected,
Bragheto et al [3] also observed an alleviation of pain and abnormal
bleeding associated with adenomyosis.
The most common complication in this study was prolonged
vaginal spotting (n ¼ 28), which mostly occurred during the ﬁrst 3
months (n ¼ 18; 64.3%), and improved as time passed. Prolonged
vaginal spotting might be associated with vessel density and/or
vascular maturity of the endometrium. High concentration of le-
vonorgestrel from the LNG-IUS is known to result in glandular at-
rophy and stromal decidualization. Therefore, during the early
postinsertion period, these effects are combinedwith inﬂammatory
changes associated with foreign body reactions, which aggravate
apoptosis of the endometrial glands and stroma, and cause
abnormal uterine bleeding [18e22]. Stephanie et al [23] reported
that an endometrium exposed to the LNG-IUS for between 1month
and 3 months showed an 11.5-fold increase in small naked vessels,
which are fragile. However, the vessel area and density increased
dramatically in a time-dependent pattern after long-term treat-
ment with the LNG-IUS. This vascular pattern change might explain
the time-dependent improvement in patients with early abnormal
uterine bleeding [23].
The LNG-IUS expulsion rate was as high as 37.5% in this study,
which is much higher than previously reported values {Bragheto
et al [3], 0% (0/29); Cho et al [12], 8.5% (4/47); Sheng et al [13], 16%
(15/94)}. The high expulsion rate may be strongly associated with
the large uterine volume observed in this study. According to
several studies, the copper IUD expulsion rate was 2e8% during the
1st year after insertion [24e26]. Risk factors for IUD expulsion
include young age, nulliparity, HMB, previous expulsion, and a
uterine sounding depth > 9 cm [27e29]. Recently, Merki-Feld et al
[30] reported that LNG-IUD expulsion was associated with parity,
hysterometry, and a history of dislocations. The mean parity and
hysterometry of their expulsion group were 2.4 cm and 8.6 cm,
respectively [30]. In our study, all LNG-IUS expulsions occurred
during the 1st year after insertion; the majority of expulsions
occurred within 6 months and was usually associated HMB. These
results are consistent with those previously reported [31,32].
Despite the high rate of expulsion in this study, 11 of 18 patients
who experienced expulsion decided to have the LNG-IUS reinserted
because of symptomatic improvement. Interestingly, although the
median uterine volume of the expulsion group was greater than
that in the without expulsion group, there was no signiﬁcant dif-
ference in uterine volume [266.5 (201e687) mL vs. 248.5
(201e384 mL); p ¼ 0.406].
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noncomparative study, and the follow-up periods among the pa-
tients were not equal, which made it difﬁcult to perform compar-
isons. Accordingly, we used Wilcoxon signed rank tests (only 2
period comparisons) instead of the Friedman tests. A future pro-
spective study is required to conﬁrm our ﬁndings. Second, we
evaluated the symptomatic changes of HMB using the VAS scale
(usually used to assess pain intensity) prior to and after inserting
the LNG-IUS rather than pictorial blood loss assessments or
changes in the hemoglobin levels. In this study, the preinsertion
hemoglobin levels were obtained from 35 of 48 patients, and 24
patients were diagnosedwith iron deﬁciency anemia. Among them,
only 13 patients were followed up and had their hemoglobin levels
measured at 3e6 months. Although the hemoglobin levels were
not available for all HMB patients, most of them experienced
symptomatic improvement in the amount of menstrual blood loss
without expulsion or removal of the LNG-IUS. Therefore, the
symptomatic changes of HBM using the VAS scale were evaluated.
Third, the sensitivity and speciﬁcity of TVS for diagnosing adeno-
myosis is 80e86% and 74e100%, respectively [16,33,34]. Fourth, the
study populations in this study were too small for generalizing the
results. The follow-up period of this study included only nine cases
at 36 months and 15 cases at 24 months. This small sample size
limited our ability to evaluate changes in the uterine volume in
patients with large adenomyosis using the LNG-IUS. Despite these
limitations, this was the ﬁrst study to evaluate the LNG-IUS in pa-
tients with large symptomatic adenomyosis. A large-scale ran-
domized study including comparisons with other conservative
treatment methods and long-term follow-up data are required to
conﬁrm our results.
In conclusion, the LNG-IUS was a considerable treatment
method for patients with large symptomatic adenomyosis. The
LNG-IUS was observed to improve dysmenorrhea and HMB over
time despite its high rate of expulsion.
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